- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 259186, 5 pages
RP105-Negative B Cells in Systemic Lupus Erythematosus
Division of Rheumatology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan
Received 25 May 2011; Accepted 19 July 2011
Academic Editor: Anisur Rahman
Copyright © 2012 Syuichi Koarada and Yoshifumi Tada. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- B. H. Hahn, “Antibodies to DNA,” New England Journal of Medicine, vol. 338, no. 19, pp. 1359–1368, 1998.
- C. A. von Muhlen and E. M. Tan, “Autoantibodies in the diagnosis of systemic rheumatic diseases,” Seminars in Arthritis and Rheumatism, vol. 24, no. 5, pp. 323–358, 1995.
- P. E. Lipsky, “Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity,” Nature Immunology, vol. 2, no. 9, pp. 764–766, 2001.
- D. S. Pisetsky, “Anti-DNA and autoantibodies,” Current Opinion in Rheumatology, vol. 12, no. 5, pp. 364–368, 2000.
- N. A. Mitchison and L. R. Wedderburn, “B cells in autoimmunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 16, pp. 8750–8751, 2000.
- K. Miyake, Y. Yamashita, Y. Hitoshi, K. Takatsu, and M. Kimoto, “Murine B cell proliferation and protection from apoptosis with an antibody against a 105-kD molecule: unresponsiveness of X-linked immunodeficient B cells,” Journal of Experimental Medicine, vol. 180, no. 4, pp. 1217–1224, 1994.
- S. Koarada, Y. Tada, O. Ushiyama et al., “B cells lacking RP105, a novel B cell antigen, in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 42, no. 12, pp. 2593–2600, 1999.
- Y. Kikuchi, S. Koarada, Y. Tada et al., “RP105-lacking B cells from lupus patients are responsible for the production of immunoglobulins and autoantibodies,” Arthritis and Rheumatism, vol. 46, no. 12, pp. 3259–3265, 2002.
- S. Divanovic, A. Trompette, S. F. Atabani et al., “Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105,” Nature Immunology, vol. 6, no. 6, pp. 571–578, 2005.
- Y. Tada, S. Koarada, F. Morito et al., “Toll-like receptor homolog RP105 modulates the antigen-presenting cell function and regulates the development of collagen-induced arthritis,” Arthritis Research and Therapy, vol. 10, no. 5, article R121, 2008.
- R. G. Lahita, Lupus, Academic Press, San Diego, Calif, USA, 5th edition, 2011.
- Y. Miura, R. Shimazu, K. Miyake et al., “RP105 is associated with MD-1 and transmits an activation signal in human B cells,” Blood, vol. 92, no. 8, pp. 2815–2822, 1998.
- A. Ishii, A. Matsuo, H. Sawa et al., “Lamprey TLRs with properties distinct from those of the variable lymphocyte receptors,” Journal of Immunology, vol. 178, no. 1, pp. 397–406, 2007.
- R. Medzhitov, P. Preston-Hurlburt, and C. A. Janeway, “A human homologue of the Drosophila toll protein signals activation of adaptive immunity,” Nature, vol. 388, no. 6640, pp. 394–397, 1997.
- A. K. Roshak, K. M. Anderson, S. D. Holmes et al., “Anti-human RP105 sera induces lymphocyte proliferation,” Journal of Leukocyte Biology, vol. 65, no. 1, pp. 43–49, 1999.
- R. Higgs, P. Cormican, S. Cahalane et al., “Induction of a novel chicken Toll-like receptor following Salmonella enterica serovar Typhimurium infection,” Infection and Immunity, vol. 74, no. 3, pp. 1692–1698, 2006.
- K. Miyake, Y. Yamashita, M. Ogata, T. Sudo, and M. Kimoto, “RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family,” Journal of Immunology, vol. 154, no. 7, pp. 3333–3340, 1995.
- K. Miyake, R. Shimazu, J. Kondo et al., “Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression,” Journal of Immunology, vol. 161, no. 3, pp. 1348–1353, 1998.
- M. Kimoto, K. Nagasawa, and K. Miyake, “Role of TLR4/MD-2 and RP105/MD-1 in innate recognition of lipopolysaccharide,” Scandinavian Journal of Infectious Diseases, vol. 35, no. 9, pp. 568–572, 2003.
- Y. Yamashita, K. Miyake, Y. Miura et al., “Activation mediated by RP105 but not CD40 makes normal B cells susceptible to anti-IgM-induced apoptosis: a role for Fc receptor coligation,” Journal of Experimental Medicine, vol. 184, no. 1, pp. 113–120, 1996.
- D. M. Klinman, “B-cell abnormalities characteristic of systemic lupus erythematosus,” in Dubois' Lupus Erythematosus, D. J. Wallece and B. H. Hahn, Eds., pp. 195–206, Williams and Wilkins, Boltimore, Md, USA, 5th edition, 1997.
- Y. Miura, K. Miyake, Y. Yamashita et al., “Molecular cloning of a human RP105 homologue and chromosomal localization of the mouse and human RP105 genes (Ly64 and LY64),” Genomics, vol. 38, no. 3, pp. 299–304, 1996.
- P. J. Maddison, T. T. Provost, and M. Reichlin, “Serological findings in patients with 'ANA-negative' systemic lupus erythematosus,” Medicine, vol. 60, no. 2, pp. 87–94, 1981.
- C. H. C. Maraina, M. D. Kamaliah, and M. Ishak, “ANA negative (Ro) lupus erythematosus with multiple major organ involvement: a case report,” Asian Pacific Journal of Allergy and Immunology, vol. 20, no. 4, pp. 279–282, 2002.
- K. Sugisaki, I. Takeda, T. Kanno et al., “An anti-nuclear antibody-negative patient with systemic lupus erythematosus (SLE) accompanied with anti-ribosomal P antibody (anti-P),” Internal Medicine, vol. 41, no. 11, pp. 1047–1051, 2002.
- M. Reichlin, “ANA negative systemic lupus erythematosus sera revisited serologically,” Lupus, vol. 9, no. 2, pp. 116–119, 2000.
- P. Khajehdehi, S. F. Islam, L. Salinas-Madrigal, et al., “Lupus nephritis in an anti-nuclear antibody-negative young male. The simultaneous presence of class III and class V renal lesions,” Clinical Nephrology, vol. 51, pp. 379–382, 1999.
- A. Zoli, L. Altomonte, A. Galossi, A. Taranto, L. Mirone, and M. Magaró, “Neurobehavioural and psychiatric manifestations in a case of ANA- negative SLE with antiphospholipid antibodies,” Clinical Rheumatology, vol. 17, no. 1, pp. 68–70, 1998.
- C. N. Morris, S. D. Calobrisi, and E. L. Matteson, “Antinuclear antibody negative lupus associated with dystrophic calcification,” The Journal of Rheumatology, vol. 25, no. 4, pp. 825–826, 1998.
- D. A. Blaustein and S. A. Blaustein, “Antinuclear antibody negative systemic lupus erythematosus presenting as bilateral facial paralysis,” Journal of Rheumatology, vol. 25, no. 4, pp. 798–800, 1998.
- S. Sircar, V. A. Taneja, and U. Kansra, “ANA-negative SLE presenting with nephritis and oculomotor palsy: a case report,” Indian Journal of Pathology and Microbiology, vol. 40, no. 4, pp. 539–542, 1997.
- S. Koarada, M. Ide, Y. Haruta et al., “Two cases of antinuclear antibody negative lupus showing increased proportion of B cells lacking RP105,” Journal of Rheumatology, vol. 32, no. 3, pp. 562–564, 2005.
- H. Ogata, I. H. Su, K. Miyake et al., “The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells,” Journal of Experimental Medicine, vol. 192, no. 1, pp. 23–29, 2000.
- Y. Nagai, T. Kobayashi, Y. Motoi et al., “The radioprotective 105/MD-1 complex links TLR2 and TLR4/MD-2 in antibody response to microbial membranes,” Journal of Immunology, vol. 174, no. 11, pp. 7043–7049, 2005.
- S. Koarada, Y. Tada, Y. Kikuchi et al., “CD180 (RP105) in rheumatic diseases,” Rheumatology, vol. 40, no. 11, pp. 1315–1316, 2001.
- R. Mantegazza and P. Bernasconi, “Cellular aspects of myositis,” Current Opinion in Rheumatology, vol. 6, no. 6, pp. 568–574, 1994.
- R. Hohlfeld, A. G. Engel, N. Goebels, and L. Behrens, “Cellular immune mechanisms in inflammatory myopathies,” Current Opinion in Rheumatology, vol. 9, no. 6, pp. 520–526, 1997.
- N. Goebels, D. Michaelis, M. Engelhardt et al., “Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis,” Journal of Clinical Investigation, vol. 97, no. 12, pp. 2905–2910, 1996.
- Y. Kikuchi, S. Koarada, Y. Tada et al., “Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells,” Annals of the Rheumatic Diseases, vol. 60, no. 12, pp. 1137–1140, 2001.
- J. M. Anaya and N. Talal, “Sjögren's syndrome and connective tissue diseases associated with other immunologic disorders,” in Arthritis and Allied Conditions: A Textbook of Rheumatology, W. J. Koopman Jr., Ed., pp. 1561–1580, Williams and Wilkins, Baltimore, Md, USA, 13th edition, 1997.
- Y. Kikuchi, S. Koarada, S. Nakamura et al., “Increase of RP105-1acking activated B cells in the peripheral blood and salivary glands in patients with Sjögren's syndrome,” Clinical and Experimental Rheumatology, vol. 26, no. 1, pp. 5–12, 2008.
- I. Calero and I. Sanz, “Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning?” Discovery Medicine, vol. 10, no. 54, pp. 416–424, 2010.
- S. Koarada, Y. Tada, Y. Sohma et al., “Autoantibody-producing RP105(-) B cells, from patients with systemic lupus erythematosus, showed more preferential expression of BCMA compared with BAFF-R than normal subjects,” Rheumatology, vol. 49, no. 4, pp. 662–670, 2010.